Valuation: AbbVie Inc.

Market Cap 454B 399B 371B 341B 641B 43,529B 649B 4,415B 1,724B 21,494B 1,704B 1,667B 74,290B P/E 2026 *
32.3x
P/E 2027 * 23.4x
Enterprise Value 510B 449B 418B 384B 720B 48,944B 730B 4,964B 1,939B 24,168B 1,916B 1,875B 83,532B EV / Sales 2026 *
7.59x
EV / Sales 2027 * 6.89x
Free-Float
95.71%
Yield 2026 *
2.68%
Yield 2027 * 2.81%
1 day+3.17%
1 week+3.44%
Current month+5.27%
1 month+4.17%
3 months+34.00%
6 months+21.14%
Current year+15.94%
1 week 252.25
Extreme 252.25
265.29
1 month 243.07
Extreme 243.07
265.29
Current year 190.75
Extreme 190.75
265.29
1 year 187.62
Extreme 187.62
265.29
3 years 135.85
Extreme 135.85
265.29
5 years 105.56
Extreme 105.56
265.29
10 years 55.06
Extreme 55.0623
265.29
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Director

62 0.0000%
6/30/26 Free

Director

134 0.0000%
5/8/26 Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+3.16%+3.44%+40.52%+75.61% 454B
+2.18%+4.08%+51.39%+166.83% 1,068B
+2.66%+9.22%+64.67%+56.88% 641B
+1.79%+9.98%+40.87%+36.27% 351B
+1.77%+3.95%+39.81%+44.60% 299B
+1.25%+4.18%+20.61%+17.69% 266B
+1.90%+2.93%-26.07%-36.88% 220B
+4.53%+7.77%+31.00%+66.98% 203B
+2.99%+2.96%+18.67%+74.51% 162B
+2.82%+1.54%+4.18%-29.79% 141B
Average +2.54%+2.28%+28.56%+47.27% 380.39B
Weighted average by Cap. +2.43%+2.67%+39.59%+77.04%

Financials

2026 *2027 *
Net sales 67.27B 59.14B 55.05B 50.56B 94.94B 6,451B 96.19B 654B 256B 3,186B 253B 247B 11,010B 72.86B 64.05B 59.62B 54.76B 103B 6,987B 104B 709B 277B 3,450B 274B 268B 11,925B
Net income 14.42B 12.68B 11.8B 10.84B 20.35B 1,383B 20.62B 140B 54.78B 683B 54.13B 52.97B 2,360B 19.25B 16.92B 15.75B 14.47B 27.16B 1,846B 27.52B 187B 73.13B 911B 72.26B 70.7B 3,150B
Net Debt 56.47B 49.64B 46.21B 42.44B 79.69B 5,415B 80.74B 549B 215B 2,674B 212B 207B 9,242B 48.27B 42.43B 39.5B 36.28B 68.12B 4,629B 69.02B 470B 183B 2,286B 181B 177B 7,900B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-28 $265.95 +3.52% 1,124,527
26-07-27 $256.91 -0.94% 5,404,809
26-07-24 $259.36 +0.95% 4,195,437
26-07-23 $256.92 +1.43% 4,623,010
26-07-22 $253.30 -1.09% 4,953,191
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
256.91USD
Average target price
267.79USD
Spread / Average Target
+4.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock